EHA Conference 2024: Pioneering Advances in Hematology

Title

High Efficacy and Favorable Safety Of CD20-Targeted CAR-T Therapy for BTK Inhibitor refractory WM/LPL

Summary

MB-106 is a 3rd-generation fully human CD20-targeting CAR-T with high response rates and a favorable safety profile in follicular lymphoma and other B-NHLs. Currently it is being tested in Waldenstrom Macroglobulinemia (Wm)/Lymphoplasmacytic Lymphoma (LPL) and showing promising results.

Title

Rocket Pharmaceuticals’s RP-L301 Pioneers Hope for Severe Pyruvate Kinase Deficiency Treatment: Encouraging Interim Results from a Global Phase I Study

Summary

RP-L301, a promising gene therapy for Pyruvate Kinase Deficiency, shows sustained and significant improvements in hemoglobin levels up to 36 months post-treatment, with normalization observed in 75% of patients. The drug has received FDA RMAT designation, marking a potential curative advancement for this rare, life-threatening disorder.

Title

CALQUENCE plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the Phase III, double-blind, placebo-controlled ECHO trial

Summary

The Phase III ECHO trial revealed that CALQUENCE, combined with bendamustine and rituximab, significantly reduces the risk of disease progression or death in elderly patients with untreated mantle cell lymphoma. The combination demonstrated improved PFS and a favorable trend in overall survival, with a safety profile consistent with known data.

Title

Linvoseltamab in the LINKER-MM1 study showed depth and durability of response at 14-month median follow-up

Summary

Linvoseltamab has demonstrated promising efficacy and manageable safety in relapsed/refractory multiple myeloma, with 71% overall response rate and significant progression-free survival in the Phase I/II LINKER-MM1 trial. The FDA's Priority Review of linvoseltamab's BLA and the EMA's ongoing review highlight its potential impact in treating heavily pretreated MM patients.

Title

Cevostamab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: Initial results from the Phase I/II CAMMA 2 study

Summary

Cevostamab, a FcRH5 x CD3 bispecific antibody, shows promise in heavily pretreated multiple myeloma, including patients resistant to BCMA-targeted therapies. Initial results from Phase I/II CAMMA 2 (NCT05535244) demonstrate an overall response rate of 67%, with manageable safety profiles like low-grade CRS, positioning it as a potential option in the evolving treatment landscape.

Title

Belamaf’s DREAMM-7 Triumphs: BVd Outshines DVd in Enhancing PFS and Response Depth for Relapsed/Refractory Multiple Myeloma

Summary

These compelling results from the DREAMM-7 trial suggest that BVd can emerge as a new standard of care at first relapse or later in the treatment of relapsed/refractory multiple myeloma. The regimen’s robust efficacy, manageable safety profile, and ease of administration make it a highly promising option for patients and clinicians alike.